Article Versions Notes

Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Pérez-Gil A, Font-Ugalde P, Galán-Gutiérrez M. Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines. Life. 2022; 12(11):1883. https://doi.org/10.3390/life12111883

Ruiz-Villaverde, Ricardo, Lourdes Rodriguez-Fernandez-Freire, Amalia Pérez-Gil, Pilar Font-Ugalde, and Manuel Galán-Gutiérrez. 2022. "Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines" Life 12, no. 11: 1883. https://doi.org/10.3390/life12111883

Ruiz-Villaverde, R., Rodriguez-Fernandez-Freire, L., Pérez-Gil, A., Font-Ugalde, P., & Galán-Gutiérrez, M. (2022). Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines. Life, 12(11), 1883. https://doi.org/10.3390/life12111883